Browsing by 키워드 : Immunotherapy
전체 결과 41건 중 1-41 번을 표시중입니다.
- 1 Article Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer 이대호 ; Adnan Nagrial ; Byoung Chul Cho ; et al 2021
- 2 Article Association of Bacillus Calmette-Guerin shortages with bladder cancer recurrence: A single-center retrospective study 김청수 ; 안한종 ; 유달산 ; et al 2020
- 3 Article Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study 2021
- 4 Article Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study 강혜진 ; 김석진 ; 김원석 ; et al 2021
- 5 Article Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial Robin Kate Kelley ; Lorenza Rimassa ; Ann-Lii Cheng ; et al 2022
- 6 Article Cancer immunotherapy by immune checkpoint blockade and its advanced application using bio-nanomaterials Dhananjay Yadav ; Minseok Kwak ; Pallavi Singh Chauhan ; et al 2022
-
7
Dissertation
CD34+ HSCs기반 인간화 마우스에서 구축한 췌장암 동소이식모델의 종양학적 특성 및 anti-PD-1 antibody 처치에 따른 종양면역학적 변화 분석
박수진
2024
- 8 Article Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors 이재련 ; Alexandra Drakaki ; Archana Agarwal ; et al 2021
- 9 Article Clinicopathologic Characteristics and Clinical Outcome of Localized Liposarcoma: A Single-Center Experience over 25 Years and Evaluation of PD-L1 Expression Heejung Chae ; Jeong Eun Kim ; Wanlim Kim ; et al 2022
- 10 Article Comparison of human peripheral blood dendritic cell activation by four fucoidans Wei Zhang ; Hae-Bin Park ; Dhananjay Yadav ; et al 2021
- 11 Article Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response 강준호 ; 김규표 ; 김기훈 ; et al 2020
- 12 Article Emerging Trends in the Treatment of Advanced Carcinoma: A 고흥규 ; 권동일 ; 김건하 ; et al 2021
- 13 Article Enhancement of Immune Checkpoint Inhibitor-Mediated Anti-Cancer Immunity by Intranasal Treatment of Ecklonia cava Fucoidan against Metastatic Lung Cancer Wei Zhang ; Juyoung Hwang ; Dhananjay Yadav ; et al 2021
- 14 Article Escherichia coli adhesion portion FimH functions as an adjuvant for cancer immunotherapy. Wei Zhang ; Li Xu ; Hae-Bin Park ; et al 2020
- 15 Article Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer Peter Schmid ; Javier Cortes ; Rebecca Dent ; et al 2022
- 16 Article Evolution of Radiological Treatment Response Assessments for Cancer Immunotherapy: From iRECIST to Radiomics and Artificial Intelligence Nari Kim ; Eun Sung Lee ; Sang Eun Won ; et al 2022
- 17 Article Expression of the immune checkpoint molecule V-set immunoglobulin domain-containing 4 is associated with poor prognosis in patients with advanced gastric cancer 김소운 ; 노진 ; 박영수 ; et al 2021
- 18 Article First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial 김상위 ; Adam Pluzanski ; Alain Vergnenegre ; et al 2021
- 19 Article First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial Sang-We Kim ; Adam Pluzanski ; Alain Vergnenegre ; et al 2022
- 20 Article High tumor hexokinase-2 expression promotes a pro-tumorigenic immune microenvironment by modulating CD8+/regulatory T-cell infiltration Sehui Kim ; Jaemoon Koh ; Seung Geun Song ; et al 2022
- 21 Article Immune Checkpoint Inhibitor with or without Radiotherapy in Melanoma Patients with Brain Metastases: A Systematic Review and Meta-Analysis 김평화 ; 서종현 ; 김호성 ; et al 2021
- 22 Article Impact of gender on response to immune checkpoint inhibitors in patients with non-small cell lung cancer undergoing second- or later-line treatment Myeong Geun Choi ; Chang-Min Choi ; Dae Ho Lee ; et al 2022
- 23 Article Impact of pseudoprogression and treatment beyond progression on outcome in patients with non-small cell lung cancer treated with immune checkpoint inhibitors 원상은 ; 박효정 ; 변상일 ; et al 2020
- 24 Article Implication of CD69(+)CD103(+) tissue-resident-like CD8(+) T cells as a potential immunotherapeutic target for cholangiocarcinoma 김상엽 ; 김형돈 ; 박성열 ; et al 2021
- 25 Article Kinetics of the neutrophil-lymphocyte ratio during PD-1 inhibition as a prognostic factor in advanced hepatocellular carcinoma 김강모 ; 김지윤 ; 류백렬 ; et al 2021
- 26 Article Late complications and quality of life assessment for survivors receiving allogeneic hematopoietic stem cell transplantation 김효진 ; 이신혜 ; 고수진 ; et al 2021
- 27 Article Major clinical research advances in gynecologic cancer in 2020 김재원 ; 박정열 ; 서동훈 ; et al 2021
- 28 Article Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma Andrew X Zhu ; Alexander R Abbas ; Marina Ruiz de Galarreta ; et al 2022
- 29 Article Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial Yoon-Koo Kang ; Li-Tzong Chen ; Min-Hee Ryu ; et al 2022
- 30 Article Nucleic acid nanotechnology for cancer treatment 진준오 ; 김규린 ; 황주영 ; et al 2020
- 31 Article Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung 김상위 ; 김우성 ; 윤신교 ; et al 2021
- 32 Article Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy Jeffrey Graham ; John Connor Wells ; Shaan Dudani ; et al 2022
- 33 Article PD-1 and PD-L1 expression in Kaposi sarcoma: A comparative study according to the pathological stage and clinical characteristics 김영재 ; 원종현 ; 이미우 ; et al 2021
- 34 Article Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Thomas Powles ; Piotr Tomczak ; Se Hoon Park ; et al 2022
- 35 Article Predictive Role of Prior Radiotherapy and Immunotherapy-Related Adverse Effects in Advanced NSCLC Patients Receiving Anti-PD-1/L1 Therapy 최창민 ; Chang Dong Yeo ; Hye Seon Kang ; et al 2021
- 36 Article Radiation pneumonitis in patients with non-small-cell lung cancer receiving chemoradiotherapy and an immune checkpoint inhibitor: a retrospective study 김성우 ; 김수산 ; 김연주 ; et al 2021
- 37 Article Radiomics-based prediction model for outcomes of PD-1/PD-L1 immunotherapy in metastatic urothelial carcinoma 김정곤 ; 박계진 ; 박범우 ; et al 2020
- 38 Article Real-world data analysis of patients with cancer of unknown primary 강소라 ; 김규표 ; 김정은 ; et al 2021
- 39 Article Risk of Hepatitis B Virus Reactivation in Patients Treated With Immunotherapy for Anti-cancer Treatment Kang Mo Kim ; Baek-Yeol Ryoo ; Ju Hyun Shim ; et al 2022
- 40 Article Stereotactic body radiation therapy for pancreatic cancer: a potential ally in the era of immunotherapy? Jin-hong Park 2022
- 41 Article Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options 박인근 ; 이재련 2020
1